Aneurysm growth, survival, and quality of life in untreated thoracic aortic aneurysms: the effective treatments for thoracic aortic aneurysms study.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 12 06 2021
revised: 02 09 2021
accepted: 11 11 2021
pubmed: 2 12 2021
medline: 6 7 2022
entrez: 1 12 2021
Statut: ppublish

Résumé

To observe, describe, and evaluate management and timing of intervention for patients with untreated thoracic aortic aneurysms. Prospective study of UK National Health Service (NHS) patients aged ≥18 years, with new/existing arch or descending thoracic aortic aneurysms of ≥4 cm diameter, followed up until death, intervention, withdrawal, or July 2019. Outcomes were aneurysm growth, survival, quality of life (using the EQ-5D-5L utility index), and hospital admissions. Between 2014 and 2018, 886 patients were recruited from 30 NHS vascular/cardiothoracic units. Maximum aneurysm diameter was in the descending aorta in 725 (82%) patients, growing at 0.2 cm (0.17-0.24) per year. Aneurysms of ≥4 cm in the arch increased by 0.07 cm (0.02-0.12) per year. Baseline diameter was related to age and comorbidities, and no clinical correlates of growth were found. During follow-up, 129 patients died, 64 from aneurysm-related events. Adjusting for age, sex, and New York Heart Association dyspnoea index, risk of death increased with aneurysm size at baseline [hazard ratio (HR): 1.88 (95% confidence interval: 1.64-2.16) per cm, P < 0.001] and with growth [HR: 2.02 (1.70-2.41) per cm, P < 0.001]. Hospital admissions increased with aneurysm size [relative risk: 1.21 (1.05-1.38) per cm, P = 0.008]. Quality of life decreased annually for each 10-year increase in age [-0.013 (-0.019 to -0.007), P < 0.001] and for current smoking [-0.043 (-0.064 to -0.023), P = 0.004]. Aneurysm size was not associated with change in quality of life. International guidelines should consider increasing monitoring intervals to 12 months for small aneurysms and increasing intervention thresholds. Individualized decisions about surveillance/intervention should consider age, sex, size, growth, patient characteristics, and surgical risk.

Identifiants

pubmed: 34849716
pii: 6446067
doi: 10.1093/eurheartj/ehab784
pmc: PMC9246658
doi:

Types de publication

Editorial Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

2356-2369

Subventions

Organisme : Department of Health
ID : 11/147/03
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentOn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Eur J Vasc Endovasc Surg. 2017 Jan;53(1):4-52
pubmed: 28081802
J Am Coll Cardiol. 2010 Apr 6;55(14):e27-e129
pubmed: 20359588
BMJ Open. 2021 Mar 4;11(3):e043323
pubmed: 33664076
Stat Med. 2012 Dec 30;31(30):4456-71
pubmed: 23037571
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Br J Surg. 2014 Sep;101(10):1244-51
pubmed: 25048981
Gen Thorac Cardiovasc Surg. 2019 Jan;67(1):59-65
pubmed: 29030719
BMJ Open. 2015 Jun 02;5(6):e008147
pubmed: 26038360
J Am Heart Assoc. 2017 Mar 14;6(3):
pubmed: 28292748
Lancet. 1998 Nov 21;352(9141):1649-55
pubmed: 9853436
Circulation. 2013 May 21;127(20):2031-7
pubmed: 23599348
Eur J Vasc Endovasc Surg. 2011 Jan;41 Suppl 1:S1-S58
pubmed: 21215940
Eur Heart J. 2014 Nov 1;35(41):2873-926
pubmed: 25173340
Health Technol Assess. 2022 Jan;26(6):1-166
pubmed: 35094747

Auteurs

Linda Sharples (L)

Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

Priya Sastry (P)

Department of Cardiac Surgery, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK.

Carol Freeman (C)

Papworth Trials Unit Collaboration, Royal Papworth Hospital NHS Foundation Trust, Papworth Road, Trumpington, Cambridge CB2 0AY, UK.

Colin Bicknell (C)

Department of Vascular Surgery, Imperial College, South Kensington Campus, London SW7 2AZ, UK.

Yi Da Chiu (YD)

Papworth Trials Unit Collaboration, Royal Papworth Hospital NHS Foundation Trust, Papworth Road, Trumpington, Cambridge CB2 0AY, UK.
MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Robinson Way, Cambridge CB2 0SR, UK.

Srinivasa Rao Vallabhaneni (SR)

Liverpool Vascular & Endovascular Service, Royal Liverpool University Hospital, Prescot Street, Liverpool, Merseyside L7 8XP, UK.

Andrew Cook (A)

Wessex Institute & Southampton Clinical Trials Unit, University of Southampton, Alpha House, Enterprise Rd, Chilworth, Southampton SO16 7NS, UK.

Joanne Gray (J)

Faculty of Health and Life Sciences, Northumbria University, Wells Close, Newcastle Upon Tyne NE7 7YT, UK.

Andrew McCarthy (A)

Faculty of Health and Life Sciences, Northumbria University, Wells Close, Newcastle Upon Tyne NE7 7YT, UK.

Peter McMeekin (P)

Faculty of Health and Life Sciences, Northumbria University, Wells Close, Newcastle Upon Tyne NE7 7YT, UK.

Luke Vale (L)

Health Economics Group, Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne NE2 4AX, UK.

Stephen Large (S)

Department of Cardiac Surgery, Royal Papworth Hospital NHS Foundation Trust, Papworth Road, Trumpington, Cambridge CB2 0AY, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH